Kiora Pharmaceuticals Advances Two Phase 2 Retinal Disease Trials, Secures $110M Asian Partnership
Key Insights
Kiora Pharmaceuticals (search) initiated two Phase 2 clinical trials for retinal diseases, including KLARITY for KIO-104 treating retinal inflammation (search) and ABACUS-2 for KIO-301 targeting vision restoration in retinitis pigmentosa (search) patients.
The company secured a strategic partnership with Senju Pharmaceutical for KIO-301 development in Asia, potentially worth up to $110 million plus royalties, while extending KIO-104 market exclusivity to 2043.
With $20.7 million in cash and projected runway into late 2027, Kiora maintains funding beyond anticipated data readouts for both trials while actively recruiting patients across multiple sites.
Kiora Pharmaceuticals (search) has made significant progress in its retinal disease pipeline, launching two Phase 2 clinical trials while securing a major international partnership that could be worth up to $110 million. The clinical-stage biotechnology company reported these developments alongside its second quarter 2025 financial results, highlighting advances in treatments for inherited retinal diseases and retinal inflammation (search).
Dual Phase 2 Trial Advancement
The company has initiated two pivotal Phase 2 studies targeting different aspects of retinal disease. The KLARITY trial is evaluating KIO-104, a next-generation, non-steroidal, immuno-modulatory small-molecule inhibitor of dihydroorotate dehydrogenase (search) (DHODH (search)), for treating patients with retinal inflammation (search) including posterior non-infectious uveitis (search) and diabetic macular edema (search).
Simultaneously, Kiora launched the ABACUS-2 Phase 2 clinical trial of KIO-301 for vision restoration in patients with retinitis pigmentosa (search). This randomized, controlled, double-masked, multiple-dose study began patient enrollment in October 2024 and represents a critical step toward potential regulatory approval for late-stage retinitis pigmentosa treatment.
"For KIO-301, having a validated functional vision assessment to serve as a critical endpoint for both ABACUS-2 and a potential registration study(s) represents both progress and promise for those affected by inherited retinal diseases," said Brian M. Strem, Ph.D., President & Chief Executive Officer of Kiora.
Strategic Asian Partnership Secured
Kiora entered into an option agreement with Senju Pharmaceutical Co., Ltd. for the development and commercialization of KIO-301 in key Asian markets, including Japan and China. The partnership carries a potential deal value of up to $110 million plus royalties if the option is exercised, significantly expanding Kiora's global commercialization network.
The company recorded $1.25 million in deferred revenue related to a non-refundable option fee from Senju as part of this partnership arrangement. Additionally, Kiora received $1.3 million in reimbursed Q1 2025 R&D expenses from Théa Open Innovation (search) for KIO-301-related activities.
Enhanced Market Protection and Clinical Design
Kiora strengthened KIO-104's market position by extending exclusivity into 2043 through receipt of a patent covering methods for optimizing treatment of ocular inflammatory diseases. This extended protection period, absent any patent term extensions, provides significant commercial runway for the asset.
The ABACUS-2 trial employs a validated efficacy endpoint to assess functional vision outcomes in patients with moderate to advanced vision loss due to retinal degeneration. These functional vision assessments are designed to serve as the approvable endpoint for future registration trials of KIO-301, streamlining the regulatory pathway.
Financial Position and Operational Outlook
Kiora ended the second quarter with $20.7 million in cash, cash equivalents and short-term investments, along with $2.4 million in collaboration receivables and $0.7 million in research incentive tax credits. The company reported a net loss of $2.2 million for the second quarter of 2025, consistent with the same period in 2024.
R&D expenses for the second quarter were $2.6 million before recognizing $1.7 million in reimbursable expenses from Théa, compared to $2.0 million in R&D expenses with $1.1 million in offsetting reimbursements in the prior year quarter. The increase was primarily attributable to clinical trial activities.
The company maintains a projected cash runway into late 2027, extending beyond anticipated data readouts for both KLARITY and ABACUS-2 trials, with potential for further extension through achievement of partnership milestones.
Pipeline Targeting Critical Unmet Needs
KIO-301 is a molecular photoswitch designed to restore vision in patients with inherited and age-related retinal degeneration, targeting conditions including retinitis pigmentosa (search), choroideremia (search), and Stargardt disease (search). The compound has the potential to become the first treatment option for patients with these inherited degenerative diseases.
Both trials are actively recruiting patients, with Kiora anticipating that many eligible patients for ABACUS-2 will come from the functional vision assessment validation study, facilitating enrollment targets and timelines. The company continues to bring online ABACUS-2 sites while the KLARITY trial recruits across several inflammatory retinal disease indications.